SETD2 inhibited T-cell acute lymphocytic leukemia invasion and infiltration by inhibiting the JAK/STAT pathway
- 5 January 2026
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (3) , 1251-1263
Abstract
T-cell acute lymphocytic leukemia (T-ALL) is a malignant transformation of immature precursor T-cells that is highly aggressive. The disruption of SETD2 is thought to be a unique epigenetic mechanism for leukemia. This study aimed to investigate the role and possible mechanism of SETD2 in T-ALL. The expression of SETD2 in T-ALL tissues and cells was detected by RT-PCR, and siRNA (si-NC/si-SETD2) and overexpressed plasmids (ov-NC/ov-SETD2) were used to transfected T-ALL cell lines JURKAT and MOLT-4, and cell proliferation, migration/invasion and cell cycle were detected by CCK8, Transwell, flow cytometry, respectively. WB was used to detect the changes in the JAK/STAT pathway. The JAK/STAT inhibitor AG490 was further used to demonstrate the role of JAK/STAT in SETD2 regulation of T-ALL. Then, the effects of SETD2 on T-ALL tissue infiltration were verified in vivo. Results showed that SETD2 was significantly lowly expressed in T-ALL, and si-SETD2 promoted the proliferation, migration, invasion, cell cycle, and activation of the JAK/STAT pathway of T-ALL cells, while overexpression of SETD2 showed the opposite inhibitory effect. The use of AG490 inhibited the promoting effect of si-SETD2 on T-ALL, suggesting that JAK/STAT was involved in the regulation of SETD2 on T-ALL. In vivo experiments further confirmed that silencing SETD2 decreased the body weight of mice and increased the infiltration of JURKAT cells in the liver, kidney, spleen, lung, and brain, while overexpression of SETD2 showed inhibitory effects. In conclusion, SETD2 played an important role in T-ALL by inhibiting the JAK/STAT pathway to inhibit T-ALL proliferation, invasion, and transfection.Keywords
Funding Information
- the incubation program of General Hospital of Western Theater command (2021-XZYG-C45)
- the incubation program of General Hospital of Western Theater command (2021-XZYG-C46)
- Sichuan Provincial Science and Technology Support Program (2024NSFSC1292)
- Sichuan Provincial Science and Technology Support Program (2021YJ0145)
- the general program of General Hospital of Western Theater Command (2021-XZYG-B32)
This publication has 38 references indexed in Scilit:
- Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case seriesAnnals of Hematology, 2023
- International Consensus Classification of acute lymphoblastic leukemia/lymphomaVirchows Archiv, 2022
- SETD2: from chromatin modifier to multipronged regulator of the genome and beyondCellular and Molecular Life Sciences, 2022
- Importance of STAT3 signalling in cancer, metastasis and therapeutic interventionsCellular Signalling, 2022
- Molecular mechanisms in governing genomic stability and tumor suppression by the SETD2 H3K36 methyltransferaseThe International Journal of Biochemistry & Cell Biology, 2022
- AG490 protects cerebral ischemia/reperfusion injury via inhibiting the JAK2/3 signaling pathwayBrain and Behavior, 2020
- Molecular markers in ALL: Clinical implicationsBest Practice & Research Clinical Haematology, 2020
- Relapsed T Cell ALL: Current Approaches and New DirectionsCurrent Hematologic Malignancy Reports, 2019
- The molecular details of cytokine signaling via the JAK/STAT pathwayProtein Science, 2018
- T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignanciesBlood Reviews, 2018